Clinical trial · Observational
Validation of the Two-minute Walk Test and the Ten-meter Walk Test in Individuals With Cancer
Comparison of the 2MWT, the 10MeWT and the 6MWT in Individuals With Cancer, a Validation Observational Study.
NCT04750148CI-TRIAL-000630032MWTOncocompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to assess the feasibility and the validity of the 2-minute walk test (2MWT) and the 10-meter walk test (10MeWT) compared to the 6-minute walk test (6MWT) for subjects with onco-hematological disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 10-meter walk test | Diagnostic Test | — | UNRESOLVED |
| 2-minute walking test | Diagnostic Test | — | UNRESOLVED |
| 6-minute walking test | Diagnostic Test | — | UNRESOLVED |
| One leg stance test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cancer
- description
- Individuals with an oncology disease will be included in the study.
- interventionNames
- Diagnostic Test: 6-minute walking test
- Diagnostic Test: 2-minute walking test
- Diagnostic Test: 10-meter walk test
- Diagnostic Test: One leg stance test
Primary outcomes (2)
- measure
- Primary endpoint: feasibility of the 2MWT and the 10MeWT
- timeFrame
- through study completion, an average of 1 year
- description
- The feasibility of the different tests will be assessed in an oncological setting.
- measure
- Primary endpoint: criterion validity with the 6MWT
- timeFrame
- through study completion, an average of 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have an onco-hematologic disease * Have medical authorization from the patient's oncologist authorizing gait tests * Participate in the HUG rehabilitation program * Be able to give consent by signature * To be of legal age * Do not present pain when walking more than 2/10 * Be able to walk with or without technical aids for a period of 6 minutes (as per patient's statement) Exclusion Criteria: * Suffer from heart problems * Bone metastases at risk of fracture * Osteoporosis at high risk of fracture * Unbalanced Hypertension (hypertension) * Not being able to carry out the walk tests in their entirety * Not being able to perform the gait tests for reasons related to the side effects of the treatments (anemia, undernutrition, vomiting, severe fatigue, risk of thrombocytopenia, pain). * Not being able to carry out the walking test because of a lack of understanding of the instructions or because of psychological problems.
References
Publications (10)
- BACKGROUNDBohannon RW, Bubela D, Magasi S, McCreath H, Wang YC, Reuben D, Rymer WZ, Gershon R. Comparison of walking performance over the first 2 minutes and the full 6 minutes of the Six-Minute Walk Test. BMC Res Notes. 2014 Apr 25;7:269. doi: 10.1186/1756-0500-7-269. PMID 24767634
- BACKGROUNDButland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982 May 29;284(6329):1607-8. doi: 10.1136/bmj.284.6329.1607. No abstract available. PMID 6805625
- BACKGROUNDChan WLS, Pin TW. Reliability, validity and minimal detectable change of 2-minute walk test, 6-minute walk test and 10-meter walk test in frail older adults with dementia. Exp Gerontol. 2019 Jan;115:9-18. doi: 10.1016/j.exger.2018.11.001. Epub 2018 Nov 10. PMID 30423359
- BACKGROUNDEden MM, Tompkins J, Verheijde JL. Reliability and a correlational analysis of the 6MWT, ten-meter walk test, thirty second sit to stand, and the linear analog scale of function in patients with head and neck cancer. Physiother Theory Pract. 2018 Mar;34(3):202-211. doi: 10.1080/09593985.2017.1390803. Epub 2017 Oct 25. PMID 29068767
- BACKGROUNDGijbels D, Eijnde BO, Feys P. Comparison of the 2- and 6-minute walk test in multiple sclerosis. Mult Scler. 2011 Oct;17(10):1269-72. doi: 10.1177/1352458511408475. Epub 2011 Jun 3. PMID 21642370
- BACKGROUNDKosak M, Smith T. Comparison of the 2-, 6-, and 12-minute walk tests in patients with stroke. J Rehabil Res Dev. 2005 Jan-Feb;42(1):103-7. doi: 10.1682/jrrd.2003.11.0171. PMID 15742254
- BACKGROUNDLeung AS, Chan KK, Sykes K, Chan KS. Reliability, validity, and responsiveness of a 2-min walk test to assess exercise capacity of COPD patients. Chest. 2006 Jul;130(1):119-25. doi: 10.1378/chest.130.1.119.